Cognitive and Mood Side Effects of Lower Urinary Tract Medication

    August 2019 in “ Expert Opinion on Drug Safety ”
    A Elif Muderrisoglu, Klaus Becher, Stephan Madersbacher, Martin C. Michel
    Image of study
    TLDR Some medications for bladder problems can cause memory issues or mood changes, and doctors should monitor these side effects.
    The document reviewed the cognitive and mood side effects of medications for lower urinary tract symptoms, finding that muscarinic receptor antagonists, especially oral oxybutynin, pose a high risk for cognitive impairment. 5α-reductase inhibitors, used also for androgenetic alopecia, were associated with depressive symptoms and possibly dementia, with these effects potentially persisting after treatment cessation. The evidence for α₁-adrenoceptor antagonists, like tamsulosin, affecting cognition was controversial and inconclusive. The document recommended careful monitoring of mental status by physicians when prescribing these medications and considering alternative treatments for at-risk patients. It also highlighted methodological issues in existing studies and the need for further research, while noting regulatory updates to prescribing information regarding the risk of depressive symptoms with 5α-reductase inhibitors. The document did not specify the number of participants in the studies reviewed.
    Discuss this study in the Community →

    Research cited in this study

    15 / 15 results

    Related Community Posts Join

    6 / 151 results

      community Hair Loss Drugs Ranked in Order of Efficacy

      in Research/Science  67 upvotes 1 year ago
      Dutasteride is likely the most effective treatment for male pattern baldness, followed by finasteride and minoxidil in various forms and dosages. Users discuss personal experiences, dosages, and potential side effects, with some considering combining treatments for better results.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community EU Shouldn't Ban Fin & Dut: PFS is NOT REAL.

      in Research/Science  11 upvotes 10 months ago
      Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.

      community Finasteride does deplete important nuero-active steroids

      in Research/Science  9 upvotes 2 years ago
      Finasteride can reduce neuroactive steroids, causing side effects like depression, anxiety, and sexual dysfunction. Some users experience persistent symptoms after stopping finasteride, while others use alternative treatments like topical solutions.

    Related Research

    1 / 1 results